Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $8.95

Certara, Inc. (NASDAQ:CERT) has received a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.2778.

A number of research analysts recently commented on the company. Barclays upped their price objective on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Morgan Stanley decreased their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Craig Hallum lowered their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. Stephens decreased their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Robert W. Baird reduced their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th.

Certara Trading Down 1.5%

NASDAQ CERT opened at $8.01 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. Certara has a one year low of $4.45 and a one year high of $13.88. The company has a 50-day simple moving average of $6.70 and a 200-day simple moving average of $6.50. The firm has a market capitalization of $1.22 billion, a PE ratio of -17.80 and a beta of 1.44.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. During the same quarter last year, the company earned $0.07 EPS. Certara’s revenue was down 10.8% compared to the same quarter last year. On average, equities analysts forecast that Certara will post 0.22 earnings per share for the current year.

Institutional Trading of Certara

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Certara in the 2nd quarter worth approximately $123,259,000. Wasatch Advisors LP grew its stake in shares of Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after buying an additional 3,865,455 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Certara by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after buying an additional 175,024 shares in the last quarter. Deerfield Management Company L.P. increased its holdings in Certara by 71.7% in the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after buying an additional 2,813,438 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Certara by 27.1% in the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after buying an additional 1,165,064 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.